@article{10902/34332,
year = {2024},
url = {https://hdl.handle.net/10902/34332},
abstract = {Hepatocellular carcinoma (HCC) is the most common primary malignancy in the liver and is the third cause of cancer-related death worldwide. Surveillance with abdominal ultrasound should be offered to individuals at high risk for developing HCC. Accurate diagnosis, staging, and liver function are crucial when determining the optimal therapeutic approach. The BCLC staging system is widely endorsed in Western countries. Managing this pathology requires a multidisciplinary, personalized approach, generally with a multimodal strategy. Surgery remains the only curative option, albeit local and systemic therapy may also increase survival when surgery is not suitable. In advanced disease, systemic treatment should be offered to patients with ECOG/PS 0-1 and Child-Pugh class A.},
organization = {Acknowledgements: The authors thank Dr Angela Lamarca (Hospital Universitario Fundación Jiménez Díaz, Madrid, Spain) and Dr Roberto Díaz Beveridge (Hospital Universitario y Politécnico la Fe, Valencia, Spain) for the review of the guidelines and validation of the level of evidence and grade of recommendations.},
publisher = {Springer-Verlag Italia},
publisher = {Clinical and Translational Oncology, 2024, 26, 2800-2811},
title = {SEOM-GEMCAD-TTD clinical guidelines for the management of hepatocarcinoma patients (2023)},
author = {López López, Carlos and Calvo, Mariona and Cámara, Juan Carlos and García-Paredes, Beatriz and Gómez-Martín, Carlos and López, Ana María and Pazo-Cid, Roberto and Sastre, Javier and Yaya, Ricardo and Feliu, Jaime},
}